

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number  
**WO 2022/204184 A1**

(43) International Publication Date  
29 September 2022 (29.09.2022)

(51) International Patent Classification:

*C07D 491/22* (2006.01) *A61K 31/4745* (2006.01)  
*C07D 519/00* (2006.01) *C07J 1/00* (2006.01)  
*A61P 35/00* (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/021390

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:

22 March 2022 (22.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

Published:

- with international search report (Art. 21(3))

(30) Priority Data:

63/165,087 23 March 2021 (23.03.2021) US

(71) Applicant: **NUVATION BIO INC.**, [US/US]; 1500 Broadway, Suite 1401, New York, New York 10036 (US).

(72) Inventors: **HUNG, David**; c/o Nuvation Bio Inc., 1500 Broadway, Suite 1401, New York, New York 10036 (US).  
**KANKANALA, Jayakanth**; c/o Nuvation Bio Inc., 1500 Broadway, Suite 1401, New York, New York 10036 (US).  
**MILLER, Christopher Paul**; c/o Nuvation Bio Inc., 1500 Broadway, Suite 1401, New York, New York 10036 (US).  
**PETTIGREW, Jeremy David**; c/o Nuvation Bio Inc., 1500 Broadway, Suite 1401, New York, New York 10036 (US).  
**PHAM, Son Minh**; c/o Nuvation Bio Inc., 1500 Broadway, Suite 1401, New York, New York 10036 (US).  
**DARWISH, Ihab S.**; c/o Nuvation Bio Inc., 1500 Broadway, Suite 1401, New York, New York 10036 (US).

(74) Agent: **TANNER, Lorna L.** et al.; SHEPPARD MULLIN RICHTER & HAMPTON LLP, 650 Town Center Drive, 10th Floor, Costa Mesa, California 92626-1993 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS

(57) Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.



WO 2022/204184 A1